missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Rituximab Recombinant Monoclonal Antibody

Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with certain autoimmune diseases and types of cancer, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, idiopathic thrombocytopenic purpura, and pemphigus vulgaris. Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death.
Specifications
Specifications
| Antigen | Rituximab Chimeric |
| Applications | ELISA, Flow Cytometry, Functional Assay |
| Classification | Recombinant Monoclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 |
| Gene Alias | IDEC-C2B8; Rituxan |
| Host Species | Human |
| Purification Method | Protein A |
| Quantity | 100 μg |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?